PIK3CA mutations are associated with reduced pathological complete response rates in primary HER2-positive breast cancer: pooled analysis of 967 patients from five prospective trials investigating lapatinib and trastuzumab-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

PIK3CA mutations are associated with reduced pathological complete response rates in primary HER2-positive breast cancer: pooled analysis of 967 patients from five prospective trials investigating lapatinib and trastuzumab

Published:2016-08 Issue:8 Volume:27 Page:1519-1525
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Loibl S.,Majewski I.,Guarneri V.,Nekljudova V.,Holmes E.,Bria E.,Denkert C.,Schem C.,Sotiriou C.,Loi S.,Untch M.,Conte P.,Bernards R.,Piccart M.,von Minckwitz G.,Baselga J.

Funder

GSK/Novartis

Roche

Sanofi-Aventis

TEVA

7th EU frame work programme

Publisher

Elsevier BV

Subject

Oncology,Hematology

Link

http://academic.oup.com/annonc/article-pdf/27/8/1519/19446700/mdw197.pdf

Reference28 articles.

1. Neoadjuvant treatment of breast cancer: maximizing pathologic complete response rates to improve prognosis;Loibl;Curr Opin Obstet Gynecol,2015

2. Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA);Schneeweiss;Ann Oncol,2013

3. The PIK3CA gene is mutated with high frequency in human breast cancers;Bachman;Cancer Biol Ther,2004

4. PIK3CA mutations are associated with lower rates of pathological complete response (pCR) to anti-HER2 therapy in primary HER2-overexpressing breast cancer;Loibl;J Clin Oncol,2014

5. PIK3CA mutations are associated with decreased benefit to neoadjuvant human epidermal growth factor receptor 2-targeted therapies in breast cancer;Majewski;J Clin Oncol,2015

Cited by 168 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Personalized treatment using predictive biomarkers in solid organ malignancies: A review;Tumori Journal;2024-08-02

2. An Analysis of PIK3CA Hotspot Mutations and Response to Neoadjuvant Therapy in Patients with Breast Cancer from Four Prospective Clinical Trials;Clinical Cancer Research;2024-06-05

3. Distinct ER and PR expression patterns significantly affect the clinical outcomes of early HER2-positive breast cancer: A real-world analysis of 871 patients treated with neoadjuvant therapy;The Breast;2024-06

4. Trastuzumab deruxtecan in breast cancer;Critical Reviews in Oncology/Hematology;2024-06

5. GeparPiPPa;Forum;2024-05-15

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3